Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia.
about
Animal Models of Maladaptive Traits: Disorders in Sensorimotor Gating and Attentional Quantifiable Responses as Possible Endophenotypes.The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophreniaUnraveling 50-Year-Old Clues Linking Neurodegeneration and Cancer to Cycad Toxins: Are microRNAs Common Mediators?Neuropathological and Reelin deficiencies in the hippocampal formation of rats exposed to MAM; differences and similarities with schizophreniaPrenatal exposure to a viral mimetic alters behavioural flexibility in male, but not female, rats.Animal Models of Psychosis: Current State and Future Directions.Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and developmentPostmortem brain: an underutilized substrate for studying severe mental illnessAnimal models of schizophrenia.Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia.The evolution of drug development in schizophrenia: past issues and future opportunities.CNTRICS final animal model task selection: control of attentionHippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia.Enrichment and training improve cognition in rats with cortical malformationsThe methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus.Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophreniaSelective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator.Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia modelMeasuring Attention in Rodents: Comparison of a Modified Signal Detection Task and the 5-Choice Serial Reaction Time TaskTiming and space usage are disrupted by amphetamine in rats maintained on DRL 24-s and DRL 72-s schedules of reinforcement.Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia.Modeling neurodevelopmental cognitive deficits in tasks with cross-species translational validityDecoupling of sleep-dependent cortical and hippocampal interactions in a neurodevelopmental model of schizophrenia.Neurodegeneration in schizophrenia.EPS Prize Lecture. Licking and liking: the assessment of hedonic responses in rodents.Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.The Utility of Impulsive Bias and Altered Decision Making as Predictors of Drug Efficacy and Target Selection: Rethinking Behavioral Screening for Antidepressant Drugs.Attentional Set-Shifting Across Species.MAM (E17) rodent developmental model of neuropsychiatric disease: disruptions in learning and dysregulation of nucleus accumbens dopamine release, but spared executive function.Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia.MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.Charting a course toward an understanding of schizophrenia.Growing knowledge: using stem cells to study developmental neurotoxicity.Inhibition of GABA synthesis in the prefrontal cortex increases locomotor activity but does not affect attention in the 5-choice serial reaction time taskReversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics.Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood.Attentional Set-Shifting Paradigm in the Rat.Infusions of Nerve Growth Factor Into the Developing Frontal Cortex Leads to Deficits in Behavioral Flexibility and Increased Perseverance.Hypofrontality and Posterior Hyperactivity in Early Schizophrenia: Imaging and Behavior in a Preclinical Model.Juvenile treatment with a novel mGluR2 agonist/mGluR3 antagonist compound, LY395756, reverses learning deficits and cognitive flexibility impairments in adults in a neurodevelopmental model of schizophrenia.
P2860
Q26765884-A08FC04B-81CC-4F21-ACC5-F596BACAFB82Q27026637-3085DA26-95A3-4123-ACC7-758B8FB74630Q28389159-310F5B8B-2DED-413A-B8A8-D093DD072F7BQ28473742-33409009-028A-47D6-B60C-DE88BA0DEBDAQ30409892-D08398D5-BB23-4DDB-B5D4-65BA1DDB719CQ30410153-699E88C7-B610-489F-AFA4-DF390CCB8E36Q30414108-301A691B-C70C-46AE-9720-BEF5D4A4D523Q30422050-D1E1EFA0-54E6-431C-9F24-E9A2A4BF9871Q30462828-A7720EBA-1CF7-4E78-945B-C2B6042530D5Q30478274-71466C1B-B414-4C92-8378-C963A12176FEQ30487850-12C1D6A2-1FD2-41DE-9635-6328FCD6C518Q30527964-32549424-12A8-4F3E-90DA-23F408AA2333Q30540732-6695583B-3048-4764-940A-E1BE88262C93Q30720494-BF076A66-1204-484A-A690-39930B9725A7Q34220102-50286B2F-5D12-4BE1-8A2A-9EF4DC982035Q35203644-D09F796F-5174-4E40-9DF2-856A57A0B42DQ35760205-2A3F2E9A-BD7C-4AA3-86BA-5C0AEC819D4AQ36219472-98C6FDD1-A8E0-4465-A5D3-B95DC6240BFAQ36460580-108A8BAF-C9BC-40BD-B4A4-CA1EA3EFFAEAQ37003769-B8F3171B-6B3A-4868-8290-52F3013E5A56Q37078047-866AF451-ADCB-4919-A7B0-B21A5BEF7B99Q37126507-1736BAC4-9991-41B6-9065-46037F023DB1Q37504454-142F11AB-85DF-4005-B434-A6F7BF2265D2Q37768444-3E37F03B-651D-406F-857B-4AB8D501A4C5Q37992161-D1CE133F-3AAF-40E3-9015-E5EEB04B930BQ38209971-738EFF30-3B08-4954-AF94-7A4456267B3FQ38677673-8ADA5722-11C0-4D9C-99B2-91A23E6459D0Q38731646-99CACF88-E320-4000-92FD-0577EEB59122Q39277083-801572AE-9185-4388-B00B-46EFC57C38F8Q39998926-88E57C4F-8C07-419B-99BE-AE84D61CDF9EQ41456540-3BC467D7-F49D-42DE-BFA0-0E1CF5429AE9Q42378290-4433751F-F7E2-4607-ADC0-1DA38B15197EQ42407798-53B64081-BC5B-4370-A36B-E8EC703EF7CEQ42409166-50971EE5-45B1-4636-A2C9-B56DB6CB3214Q46840298-C3CBF208-B247-4005-AC0A-EADBFECB8A35Q47973666-EBC48E91-07A5-4616-9FCF-9A21549326A7Q48079038-23890099-6027-4B2C-B7F0-AEE8B6CD6F84Q48593032-968F933F-DEF0-42C7-8EB0-4B36C213DA10Q48607671-1023CC54-7A30-47F3-9916-90E484A6B2CFQ48827728-7CF7FB33-0A44-4AFD-BA11-EC5B347CD52F
P2860
Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Gestational methylazoxymethano ...... s: parallels to schizophrenia.
@en
Gestational methylazoxymethano ...... s: parallels to schizophrenia.
@nl
type
label
Gestational methylazoxymethano ...... s: parallels to schizophrenia.
@en
Gestational methylazoxymethano ...... s: parallels to schizophrenia.
@nl
prefLabel
Gestational methylazoxymethano ...... s: parallels to schizophrenia.
@en
Gestational methylazoxymethano ...... s: parallels to schizophrenia.
@nl
P2093
P2860
P356
P1476
Gestational methylazoxymethano ...... s: parallels to schizophrenia.
@en
P2093
José N Nobrega
Paul J Fletcher
Robert E Featherstone
P2860
P2888
P304
P356
10.1038/SJ.NPP.1301223
P407
P50
P577
2006-10-11T00:00:00Z